[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-377412-105":59,"doc-detail-377412-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unveiling-therapeutic-targets-for-esophageal-cancer-a-comprehensive-review","Unveiling Therapeutic Targets for Esophageal Cancer - A Comprehensive Review","","Esophageal cancer is an aggressive and deadly malignancy and remains a leading global cause of cancer-related death, with poor prognosis despite therapeutic progress. Management requires a multidisciplinary, stage-dependent plan, using surgery or endoscopic approaches for localized disease and systemic strategies such as chemoradiotherapy and targeted drug therapy for advanced settings. Key actionable molecular markers include HER2 and EGFR, with drugs like trastuzumab, cetuximab, and promising immune checkpoint blockade via pembrolizumab and nivolumab. The review also highlights epigenetic modifications, emphasizes early diagnosis, and notes the need for continued targeted-drug development with minimal side effects to improve outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unveiling-therapeutic-targets-for-esophageal-cancer-a-comprehensive-review/377412/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unveiling-therapeutic-targets-for-esophageal-cancer-a-comprehensive-review/377412.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is a multidisciplinary approach important for esophageal cancer treatment?","Question",{"text":112,"@type":113},"The document emphasizes that complete remission depends on combining multiple modalities. Treatment options are selected according to disease stage and other patient factors, requiring coordination across surgical, endoscopic, systemic, and supportive care.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular markers and corresponding therapies are discussed as therapeutic targets?",{"text":117,"@type":113},"HER2 and EGFR are highlighted as actionable molecular markers. The review mentions targeting with drugs such as trastuzumab and cetuximab, and notes that EGFR-signaling inhibitors can provide therapeutic options.",{"name":119,"@type":110,"acceptedAnswer":120},"Which immunotherapy drugs are mentioned, and what do they target?",{"text":121,"@type":113},"Pembrolizumab and nivolumab are presented as promising immunotherapy drugs. They are described as targeting immune checkpoint proteins to support anti-tumor responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},377412,1790526354,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nUnveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review  \nRakesh Acharya 1, Ananya Mahapatra 1, Henu Kumar Verma 2 and L. V. K. S. Bhaskar 1, *  \nCitation: Acharya, R.; Mahapatra, A.; Verma, H.K.; Bhaskar, L.V.K.S. Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review. Curr. Oncol. 2023, 30, 9542–9568. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/curroncol30110691](10.3390/curroncol30110691)  \nReceived: 12 September 2023  \nRevised: 19 October 2023  \nAccepted: 27 October 2023  \nPublished: 30 October 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495009, India; [rakeshacharya090@gmail.com](rakeshacharya090@gmail.com) (R.A.); [biranchinarayanmahapatra0@gmail.com](biranchinarayanmahapatra0@gmail.com) (A.M.)  \n2 Department of Immunopathology, Institute of lungs Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Neuherberg, 85764 Munich, Germany; [henukumar.verma@helmholtz-munich.de](henukumar.verma@helmholtz-munich.de)  \n* Correspondence: [lvksbhaskar@gmail.com or bhaskar.lvks@ggu.ac.in](lvksbhaskar@gmail.com or bhaskar.lvks@ggu.ac.in)  \nAbstract: Esophageal cancer is a highly aggressive and deadly disease, ranking as the sixth leading cause of cancer-related deaths worldwide. Despite advances in treatment, the prognosis remains poor. A multidisciplinary approach is crucial for achieving complete remission, with treatment options varying based on disease stage. Surgical intervention and endoscopic treatment are used for localized cancer, while systemic treatments like chemoradiotherapy and targeted drug therapy play a crucial role. Molecular markers such as HER2 and EGFR can be targeted with drugs like trastuzumaband cetuximab, and immunotherapy drugs like pembrolizumab and nivolumab show promise by targeting immune checkpoint proteins. Epigenetic modifications offer new avenues for targeted therapy. Treatment selection depends on factors like stage, tumor location, and patient health, with post-operative and rehabilitation care being essential. Early diagnosis, appropriate treatment, and supportive care are key to improving outcomes. Continued research is needed to develop effective targeted drugs with minimal side effects. This review serves as a valuable resource for clinicians and researchers dedicated to enhancing esophageal cancer treatment outcomes.  \nKeywords: esophageal cancer; multidisciplinary approach; prognosis; molecular markers; targeted ttherapy  \n1. Introduction  \nEsophageal cancer (EC) is defined by an uncontrolled growth of tissues in the muscular hollow channel separating the throat from the stomach known as the esophageal wall. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two primary histological forms [1] . While EAC develops from glandular cells and mostly affects the lower esophagus, ESCC begins in the squamous epithelial cells lining the esophagus and primarily affects the upper and middle portions. Esophageal cancer is the seventh most prevalent cancer in terms of incidence and the sixth most common cause of cancer-related deaths globally [2] . According to recent studies, 90% of EC cases globally are caused by ESCC, which is particularly common in areas referred to as the “EC belt”, encompassing sections of China, Iran, and central Asian republics [3] . On the other hand, EAC is more commonly observed in Western industrialized countries [4] .  \nThe risk factors for EAC include gastroesophageal reflux disease (GERD) and obesity, which is associated with the development or exacerbation of GERD [5] . ","cbCailJmiLBk637k","https://ap.wps.com/l/cbCailJmiLBk637k","pdf",656191,27,"English","# Introduction\n## Risk factors and disease classification\n## Treatment strategies and therapeutic targets\n# Abstract\n# Keywords","[{\"question\":\"Why is a multidisciplinary approach important for esophageal cancer treatment?\",\"answer\":\"The document emphasizes that complete remission depends on combining multiple modalities. Treatment options are selected according to disease stage and other patient factors, requiring coordination across surgical, endoscopic, systemic, and supportive care.\"},{\"question\":\"What molecular markers and corresponding therapies are discussed as therapeutic targets?\",\"answer\":\"HER2 and EGFR are highlighted as actionable molecular markers. The review mentions targeting with drugs such as trastuzumab and cetuximab, and notes that EGFR-signaling inhibitors can provide therapeutic options.\"},{\"question\":\"Which immunotherapy drugs are mentioned, and what do they target?\",\"answer\":\"Pembrolizumab and nivolumab are presented as promising immunotherapy drugs. They are described as targeting immune checkpoint proteins to support anti-tumor responses.\"}]","Unveiling Therapeutic Targets for Esophageal Cancer - A Comprehensive Review | PDF",1790224803,68]